FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2986278323> ?p ?o ?g. }

• W2986278323 abstract "Abstract Glioblastoma multiforme (GBM) is an aggressive brain tumor with a poor prognosis. Standard of care at diagnosis is surgical resection, followed by radiation and temozolomide. Receiving this therapy, the median survival is 14.6 months [1]. We have no standard treatment for relapse and known options have limited effect. There is an urgent need for novel treatment interventions to improve clinical outcomes and quality of life. Recently, improved overall survival has been achieved with immune therapeutics in melanoma and renal cell carcinoma. Accordingly, it has been posited that immunotherapy may offer promise in other difficult cancers such as GBM [2]. We present our translational study; a phase II open label, two-armed translational study of Nivolumab and Bevacizumab for recurrent GBM, who have failed Stupp’s regime [1]. Patients are included in two arms depending on possibly salvage neurosurgical resection. Both arms receive Nivolumab and Bevacizumab administrated every second weekend, but the surgical arm also receive Nivolumab 7 days prior surgery. We expect 40 patients; 20 in each arm. Enrollment period is expected to 20 months, started October 2018. Our primary objective is to make preliminary assessment of immune related biomarkers, including PD-L1; therefore, we perform full genome sequencing on tumor biopsies from the surgical arm and on blood samples from both arms. We evaluate changes in the transcriptomic landscape caused by the check-point inhibition and relation to response as compared with baseline sequencing data, as well as the impact of tumor mutation burden and neoepitope load. We investigate the tumor microenvironment by harvesting tumor infiltrating lymphocytes and study the composition by flow-cytometry. The patients are evaluated by blood samples, FET-PET as wells as clinical examinations to evaluate PFS and OS. Overall the study will provide us with a unique possibility to investigate and thereof predict which patients will profit from the treatment." @default.
• W2986278323 created "2019-11-22" @default.
• W2986278323 creator A5004172331 @default.
• W2986278323 creator A5023057632 @default.
• W2986278323 creator A5033440492 @default.
• W2986278323 creator A5054574870 @default.
• W2986278323 creator A5064526658 @default.
• W2986278323 creator A5064975863 @default.
• W2986278323 creator A5071073233 @default.
• W2986278323 creator A5073488854 @default.
• W2986278323 creator A5077199450 @default.
• W2986278323 creator A5087170219 @default.
• W2986278323 date "2019-11-01" @default.
• W2986278323 modified "2023-10-07" @default.
• W2986278323 title "ATIM-01. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; A TRANSLATIONAL TRIAL IN PROGRESS" @default.
• W2986278323 doi "https://doi.org/10.1093/neuonc/noz175.001" @default.
• W2986278323 hasPublicationYear "2019" @default.
• W2986278323 type Work @default.
• W2986278323 sameAs 2986278323 @default.
• W2986278323 citedByCount "0" @default.
• W2986278323 crossrefType "journal-article" @default.
• W2986278323 hasAuthorship W2986278323A5004172331 @default.
• W2986278323 hasAuthorship W2986278323A5023057632 @default.
• W2986278323 hasAuthorship W2986278323A5033440492 @default.
• W2986278323 hasAuthorship W2986278323A5054574870 @default.
• W2986278323 hasAuthorship W2986278323A5064526658 @default.
• W2986278323 hasAuthorship W2986278323A5064975863 @default.
• W2986278323 hasAuthorship W2986278323A5071073233 @default.
• W2986278323 hasAuthorship W2986278323A5073488854 @default.
• W2986278323 hasAuthorship W2986278323A5077199450 @default.
• W2986278323 hasAuthorship W2986278323A5087170219 @default.
• W2986278323 hasBestOaLocation W29862783231 @default.
• W2986278323 hasConcept C121608353 @default.
• W2986278323 hasConcept C126322002 @default.
• W2986278323 hasConcept C128544194 @default.
• W2986278323 hasConcept C142724271 @default.
• W2986278323 hasConcept C143998085 @default.
• W2986278323 hasConcept C2776194525 @default.
• W2986278323 hasConcept C2776694085 @default.
• W2986278323 hasConcept C2777701055 @default.
• W2986278323 hasConcept C2777802072 @default.
• W2986278323 hasConcept C2780030458 @default.
• W2986278323 hasConcept C502942594 @default.
• W2986278323 hasConcept C71924100 @default.
• W2986278323 hasConceptScore W2986278323C121608353 @default.
• W2986278323 hasConceptScore W2986278323C126322002 @default.
• W2986278323 hasConceptScore W2986278323C128544194 @default.
• W2986278323 hasConceptScore W2986278323C142724271 @default.
• W2986278323 hasConceptScore W2986278323C143998085 @default.
• W2986278323 hasConceptScore W2986278323C2776194525 @default.
• W2986278323 hasConceptScore W2986278323C2776694085 @default.
• W2986278323 hasConceptScore W2986278323C2777701055 @default.
• W2986278323 hasConceptScore W2986278323C2777802072 @default.
• W2986278323 hasConceptScore W2986278323C2780030458 @default.
• W2986278323 hasConceptScore W2986278323C502942594 @default.
• W2986278323 hasConceptScore W2986278323C71924100 @default.
• W2986278323 hasLocation W29862783231 @default.
• W2986278323 hasLocation W29862783232 @default.
• W2986278323 hasOpenAccess W2986278323 @default.
• W2986278323 hasPrimaryLocation W29862783231 @default.
• W2986278323 isParatext "false" @default.
• W2986278323 isRetracted "false" @default.
• W2986278323 magId "2986278323" @default.
• W2986278323 workType "article" @default.